These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2794863)
1. Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. Breathnach SM; Kofler H; Sepp N; Ashworth J; Woodrow D; Pepys MB; Hintner H J Exp Med; 1989 Oct; 170(4):1433-8. PubMed ID: 2794863 [TBL] [Abstract][Full Text] [Related]
2. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Pepys MB; Booth SE; Tennent GA; Butler PJ; Williams DG Clin Exp Immunol; 1994 Jul; 97(1):152-7. PubMed ID: 8033412 [TBL] [Abstract][Full Text] [Related]
3. Complexes of serum amyloid P component and DNA in serum from healthy individuals and systemic lupus erythematosus patients. Sørensen IJ; Holm Nielsen E; Schrøder L; Voss A; Horváth L; Svehag SE J Clin Immunol; 2000 Nov; 20(6):408-15. PubMed ID: 11202230 [TBL] [Abstract][Full Text] [Related]
4. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Bickerstaff MC; Botto M; Hutchinson WL; Herbert J; Tennent GA; Bybee A; Mitchell DA; Cook HT; Butler PJ; Walport MJ; Pepys MB Nat Med; 1999 Jun; 5(6):694-7. PubMed ID: 10371509 [TBL] [Abstract][Full Text] [Related]
6. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies. Voss A; Nielsen EH; Svehag SE; Junker P J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838 [TBL] [Abstract][Full Text] [Related]
7. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Pepys MB; Butler PJ Biochem Biophys Res Commun; 1987 Oct; 148(1):308-13. PubMed ID: 3675579 [TBL] [Abstract][Full Text] [Related]
8. Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. Hintner H; Booker J; Ashworth J; Auböck J; Pepys MB; Breathnach SM J Invest Dermatol; 1988 Jul; 91(1):22-8. PubMed ID: 2455001 [TBL] [Abstract][Full Text] [Related]
10. Chromatin-independent binding of serum amyloid P component to apoptotic cells. Familian A; Zwart B; Huisman HG; Rensink I; Roem D; Hordijk PL; Aarden LA; Hack CE J Immunol; 2001 Jul; 167(2):647-54. PubMed ID: 11441067 [TBL] [Abstract][Full Text] [Related]
11. Pentraxin binding to isolated rat liver nuclei. Shephard EG; Smith PJ; Coetzee S; Strachan AF; de Beer FC Biochem J; 1991 Oct; 279 ( Pt 1)(Pt 1):257-62. PubMed ID: 1930144 [TBL] [Abstract][Full Text] [Related]
12. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. Hamazaki H J Biol Chem; 1995 May; 270(18):10392-4. PubMed ID: 7737971 [TBL] [Abstract][Full Text] [Related]
13. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Hutchinson WL; Hohenester E; Pepys MB Mol Med; 2000 Jun; 6(6):482-93. PubMed ID: 10972085 [TBL] [Abstract][Full Text] [Related]
14. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Bijl M; Horst G; Bijzet J; Bootsma H; Limburg PC; Kallenberg CG Arthritis Rheum; 2003 Jan; 48(1):248-54. PubMed ID: 12528126 [TBL] [Abstract][Full Text] [Related]
15. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684 [TBL] [Abstract][Full Text] [Related]
16. Serum amyloid P component binds to histones and activates the classical complement pathway. Hicks PS; Saunero-Nava L; Du Clos TW; Mold C J Immunol; 1992 Dec; 149(11):3689-94. PubMed ID: 1431140 [TBL] [Abstract][Full Text] [Related]
17. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Gillmore JD; Hutchinson WL; Herbert J; Bybee A; Mitchell DA; Hasserjian RP; Yamamura K; Suzuki M; Sabin CA; Pepys MB Immunology; 2004 Jun; 112(2):255-64. PubMed ID: 15147569 [TBL] [Abstract][Full Text] [Related]
18. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Bijl M; Bootsma H; Van Der Geld Y; Limburg PC; Kallenberg CG; Van Rijswijk MH Ann Rheum Dis; 2004 Jul; 63(7):831-5. PubMed ID: 15194579 [TBL] [Abstract][Full Text] [Related]
19. Structural, quantitative and functional comparison of amyloid P component in sera from patients with systemic lupus erythematosus and healthy donors. Sen JW; Recke C; Rahbek L; Skogstrand K; Heegaard NH Scand J Immunol; 2002 Dec; 56(6):645-51. PubMed ID: 12472678 [TBL] [Abstract][Full Text] [Related]
20. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]